• Alcon outlined new dry eye research tied to TRYPTYR (acoltremon) 0.003% ahead of Academy 2026 in Anaheim.
• Findings will be presented Sept. 30–Oct. 3, focusing on patient-reported quality of life, daily functioning, symptoms, and treatment satisfaction.
• Additional posters will compare outcomes across Alcon’s prescription and over-the-counter dry eye portfolio, including tear film-related measures.
• The update follows the U.S. launch of TRYPTYR, signaling continued commercial investment in evidence generation to support uptake.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alcon AG published the original content used to generate this news brief on September 29, 2026, and is solely responsible for the information contained therein.